ArticleJournal of molecular histology2026
The long non-coding RNA PVT1 promotes keratinocyte proliferation and inflammation in psoriasis by targeting miR-485-5p.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is an immune-mediated skin disease whose pathogenesis involves aberrant keratinocyte proliferation and immune dysregulation. The long non-coding RNA PVT1 has been implicated in various diseases, but its specific role in psoriasis remains unclear. The objectives of this study were to investigate the expression and functional role of PVT1 in psoriasis, and to explore its potential interaction with miR-485-5p. The PVT1 expression level in blood serum of psoriasis patients and healthy controls were detected by RT-qPCR. A psoriasis model in vitro was established by stimulating HaCaT keratinocytes with the M5. PVT1 was knocked down by transfecting siRNA. Functional assays included CCK-8 for proliferation, ELISA for inflammatory factors/chemokines, and dual-luciferase reporter assay for target verification. PVT1 was significantly upregulated in psoriasis patients, with expression levels positively correlating with psoriasis severity. In M5-stimulated HaCaT cells, PVT1 knockdown suppressed keratinocyte hyperproliferation and reduced the secretion of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and chemokines (CXCL1, CXCL8, CCL20). Mechanistically, PVT1 was confirmed to directly bind to and negatively regulate miR-485-5p, which was downregulated in patient samples. Rescue experiments co-transfecting si-PVT1 and miR-485-5p inhibitor partially reversed the suppressive effects of PVT1 knockdown. PVT1 was overexpressed in psoriasis and promoted disease progression by enhancing keratinocyte proliferation, inflammatory responses and chemokine, likely through the targeted downregulation of miR-485-5p. These findings suggested the PVT1/miR-485-5p axis may be a promising target for psoriasis therapy.
Indexed as
Identifiers
42185566What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.